top of page
Executive Spotlights

Orion and Merck Secure $1.63B Agreement

Rahway, NJ, July 1, 2024 (Business Wire) -- Merck (NYSE: MRK), known as MSD outside the U.S. and Canada, and Orion Corporation ("Orion") have agreed to convert their co-development and co-commercialization agreement for opevesostat (MK-5684/ODM-208) and other CYP11A1-targeting candidates into an exclusive global license for Merck. Under this agreement, Orion is eligible for up to $1.63 billion in milestone payments: $30 million for development, $625 million for regulatory, and $975 million for sales-based milestones. Orion will also receive tiered royalties ranging from low double-digits to low twenties on net sales of any licensed product.

Read full article here.

Recent Posts

See All

Radiant Vision Systems Appoints new CEO

Redmond, WA, July 1, 2024 (Radiant) -- Radiant Vision Systems has appointed Stone Jiang as their new CEO, succeeding Doug Kreysar who is retiring. Jiang, previously the Executive Vice President and

Rober A. Michael takes the helm as CEO of AbbVie

North Chicago, IL, July 1, 2024 (PRNewswire) -- AbbVie has named Robert A. Michael as its new CEO and board member, effective. He takes over from Richard A. Gonzalez, who now serves as executive cha


Life Science Headlines
bottom of page